Completed PHASE2 INTERVENTIONAL NCT01554059

Neoadjuvant Chemoradiation With Bevacizumab for Chinese Rectal Cancer Patients (New Beat)

Phase II Trial of Neoadjuvant Chemoradiation With Bevacizumab for Chinese Locally Advanced Rectal Adenocarcinoma

Sponsor: Sixth Affiliated Hospital, Sun Yat-sen University

Interventions 5-FU Bevacizumab Oxaliplatin Radiotherapy

Updated 5 times since 2017 Last updated: Nov 7, 2014 Started: Mar 31, 2012 Primary completion: May 31, 2013 Completion: Aug 31, 2014

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Listed as NCT01554059, this PHASE2 trial focuses on Rectal Adenocarcinoma and remains completed. Sponsored by Sixth Affiliated Hospital, Sun Yat-sen University, it has been updated 5 times since 2012, reflecting limited change activity. This study contributes to the evolving evidence base for cancer treatment protocols.

Status Flow

Change History

5 versions recorded

Sep 2024 — Present [monthly]

Completed PHASE2
Jul 2024 — Sep 2024 [monthly]

Completed PHASE2
Jan 2021 — Jul 2024 [monthly]

Completed PHASE2
Jun 2018 — Jan 2021 [monthly]

Completed PHASE2
Jan 2017 — Jun 2018 [monthly]

Completed PHASE2

First recorded

Mar 2012

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Sixth Affiliated Hospital, Sun Yat-sen University

Data source: Sixth Affiliated Hospital, Sun Yat-sen University

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Guangzhou, China